Amicus Therapeutics is growing steadily with Galafold and a promising Pompe therapy, targeting $1B revenue by 2028. See why ...

Swiss pharma company Idorsia (SIX: IDIA) today announced the appointment of Dr Srishti Gupta as chief executive (CEO), ...

Ad hoc announcement pursuant to Art. 53 LR André C. Muller, current CEO of Idorsia, to retire and act as an advisor to the company to ensure a smooth transition Allschwil, Switzerland - June 10 ...

Ad hoc announcement pursuant to Art. 53 LR André C. Muller, current CEO of Idorsia, to retire and act as an advisor to the ...

Significant reductions in proteinuria, estimated glomerular filtration rate stability of the C3/C3b inhibitor were also ...

Ad hoc announcement pursuant to Art. 53 LR Bondholder meetings will take place on Wednesday, June 25, 2025, to vote on proposals to amend the terms of the two outstanding convertible bonds CB 2025 ...

Ad hoc announcement pursuant to Art. 53 LR Bondholder meetings will take place on Wednesday, June 25, 2025, to vote on proposals to amend the ...

This symposium, ‘A case-based approach to navigating treatment switch in late-onset Pompe Disease (LOPD)’, was held at the ...

Drugs that target wakefulness, molecules in cannabis and wearable devices that modulate brain activity could help people with insomnia ...

Pratteln, Switzerland, January 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that Idorsia Pharmaceuticals has entered into a royalty monetization agreement with the R-Bridge Healthcare ...

Pratteln, Switzerland, January 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that Idorsia Pharmaceuticals has entered into a royalty monetization agreement with the R-Bridge ...